You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The project is informing participants of familial hypercholesterolemia genetic test results, and hereditary breast and ovarian cancer, and Lynch syndrome results will follow.
ADx Healthcare is selling an APOE test on the Helix marketplace, while HealthLytix and Dash Genomics are marketing a polygenic hazard score for late-onset Alzheimer's.
23andMe is evaluating how third-party services are impacting customers' experiences and would like to see those services be more complementary to its own efforts.
Indian DTC genomics company Mapmygenome has enlisted Israel-based Digital DNAtix to move its interpretation and personalized medicine services to a blockchain.
Researchers led by MD Anderson’s Karen Lu want to know the most efficient genetic counseling strategy as more people are getting screened for cancer risk genes.
Large-scale population sequencing projects and consumer genomics markets are picking up and oncology continues to be a strong market for Illumina.
With the help of AI, blockchain, and a new cryptocurrency, Nebula wants to give patients more control of their genomic data.
George Church's Nebula is teaming with Hong Kong startup Longenesis to create a secure platform for individuals and biobanks to sell access to their genomes.
Luna DNA, which offers a cryptocurrency to reward people for sharing biological and medical data with researchers, has raised $4 million to date.
Startup Seqster will offer its personal health records platform for donors to manage EHR, wearables, and genomic information through the blood bank's web portal.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.